Wedbush Downgrades Clinical Data (CLDA) to Neutral; Forest Buying CLDA for $30 Plus CVR,
Tweet Send to a Friend
Wedbush downgraded Clinical Data (NASDAQ: CLDA) from Outperform to Neutral. PT cut from $42 to $31.
Wedbush analyst says, "Forest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Wedbush analyst says, "Forest ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
